

1 **Metabolic adaptations in skeletal muscle after 84 days bed rest with**
2 **and without concurrent flywheel resistance exercise**

3

4 José M. Irimia^{2*}, Mario Guerrero^{1*}, Paula Rodriguez-Miguel³, Joan A. Cadefau¹, Per
5 A. Tesch³, Roser Cussó¹, Rodrigo Fernandez-Gonzalo³

6

7 ¹ *Department of Biomedicine, Barcelona University, Barcelona, Spain*

8 ² *Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis,*
9 *Indiana, USA*

10 ³ *Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden*

11

12 *: J.M. Irimia and M. Guerrero contributed equally to this work and share the first
13 authorship

14

15

16

17

18 **Running Head:** Metabolic adaptations to 84 d bed rest

19

20

21

22

23 **Corresponding author:**

24 Prof. Roser Cussó

25 Department of Biomedicine

26 Barcelona University

27 C/ Casanova 143,

28 08036, Barcelona, Spain

29 E-mail: Phone number: 606801734

30 Fax number: 34 934035882

31

This is the author's manuscript of the article published in final edited form as:

Irimia, J. M., Guerrero, M., Rodriguez-Miguel, P., Cadefau, J. A., Tesch, P. A., Cussó, R., & Fernandez-Gonzalo, R. (2017). Metabolic adaptations in skeletal muscle after 84 days of bed rest with and without concurrent flywheel resistance exercise. *Journal of Applied Physiology*, 122(1), 96-103. <https://doi.org/10.1152/jappphysiol.00521.2016>

34 **ABSTRACT**

35 As metabolic changes in human skeletal muscle after long-term (simulated) spaceflight
36 are not well understood, this study examined the effects of long-term microgravity, with
37 and without concurrent resistance exercise on skeletal muscle oxidative and glycolytic
38 capacity. Twenty-one men were subjected to 84 days head-down tilt bed rest with
39 (BRE; n=9) or without (BR; n=12) concurrent flywheel resistance exercise. Activity and
40 gene expression of glycogen synthase, glycogen phosphorylase (GPh), hexokinase,
41 phosphofructokinase-1 (PFK-1) and citrate synthase (CS), as well as gene expression of
42 succinate dehydrogenase (SDH), vascular endothelial growth factor (VEGF),
43 peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1 α) and
44 myostatin, were analysed in samples from m. vastus lateralis collected before and after
45 bed rest. Activity and gene expression of enzymes controlling oxidative metabolism
46 (CS, SDH) decreased in BR, but were partially maintained in BRE. Activity of enzymes
47 regulating anaerobic glycolysis (GPh, PFK-1) was unchanged in BR. Resistance
48 exercise increased the activity of GPh. PGC-1 α and VEGF expression decreased in both
49 BR and BRE. Myostatin increased in BR, but decreased in BRE, after bed rest. The
50 analyses of these unique samples indicate that long-term microgravity induces marked
51 alterations in the oxidative, but not the glycolytic, energy system. The proposed
52 flywheel resistance exercise was effective in counteracting some of the metabolic
53 alterations triggered by 84-d bed rest. Given the disparity between gene expression vs.
54 enzyme activity in several key metabolic markers, post-transcriptional mechanisms
55 should be explored to fully evaluate metabolic adaptations to long-term microgravity
56 with/without exercise countermeasures in human skeletal muscle.

57

58 **Keywords:** microgravity, glucose metabolism, eccentric-overload, spaceflight.

59 **INTRODUCTION**

60

61 The consequences of microgravity on human skeletal muscle contractile content,
62 function and morphology are well documented (1, 19, 37, 51). In contrast, microgravity-
63 induced alterations of skeletal muscle metabolic processes are less understood. In space-
64 flown rats, past studies reported reduced oxidative capacity of skeletal muscle (4, 50),
65 and investigations using animal models of unloading (i.e. hindlimb suspension) showed
66 decreased mitochondrial enzyme activity, predominantly in fast-type muscles, together
67 with an unchanged or even increased activity of glycolytic enzymes in skeletal muscle
68 (46, 50). In humans, long periods of unloading seem to induce a shift towards a
69 glycolytic muscle type (i.e. increased preponderance of type II fibers) (55). Indeed, the
70 few studies analyzing unloading-induced metabolic changes in human skeletal muscle
71 showed decreased citrate synthase (CS) activity, reduced capillary and mitochondrial
72 density (5, 20), and increased phosphofructokinase (PFK) mRNA expression (12).
73 Apart from alterations in metabolic enzymes, the expression of key molecular markers
74 controlling mitochondrial biogenesis (peroxisome proliferator-activated receptor gamma
75 coactivator-1; PGC-1 α) and angiogenesis (vascular endothelial growth factor; VEGF) is
76 reduced after 3-5 weeks of unloading (8, 12). This may further compromise the capacity
77 of skeletal muscle to produce energy through oxidative metabolism. While these data
78 support the notion of an enhanced reliance upon glycolysis at the expense of diminished
79 oxidative potential after several weeks of microgravity exposure, the metabolic
80 consequences of extended periods (i.e. months) of unloading in human skeletal muscle
81 remain to be elucidated. Such information is critical in order to plan future long-term,
82 exploratory space missions.

83

84 To counteract the deleterious effects of microgravity in skeletal muscle health and
85 function, different exercise interventions (resistance exercise; aerobic exercise, whole
86 body vibration) have been proposed (48, 54). According to the traditional understanding
87 of exercise adaptations, high-volume, low-intensity aerobic exercise would be efficient
88 in counteracting metabolic changes in skeletal muscle (16). However, low-volume,
89 high-intensity aerobic exercise preserved oxidative potential in astronauts on the
90 International Space Station, as indicated by maintained peak oxygen uptake, to a greater
91 extent than protocols calling for larger exercise volume (33). Even more surprising,
92 high-intensity, low-volume flywheel RE, originally designed to combat compromised
93 muscle force and size during microgravity (3, 53), was sufficient to rescue the decreased
94 expression of PGC-1 α and VEGF after 5 week unilateral lower limb suspension (12).
95 These results infer augmented muscle adaptability in response to unloading, regardless
96 of the stimulus imposed. While intriguing, such hypothesis needs to be tested during
97 systemic, long-term unloading.

98

99 In an attempt to reveal the long-term microgravity-induced skeletal muscle metabolic
100 alterations in humans, we examined muscle samples from subjects who had undertaken
101 84 days of bed rest, with or without concurrent flywheel RE. Previously, we and others
102 have reported changes in muscle volume and function (3, 44, 45), and single muscle
103 fiber properties (15, 55) in this population. The specific aim of the current study was to
104 investigate skeletal muscle oxidative and glycolytic capacity in response to 84 days
105 head-down tilt bed rest with or without concurrent flywheel RE. Given our previous
106 results employing flywheel RE in unloaded muscle (12), we hypothesized that i) long-
107 term bed rest would reduce enzyme activity and molecular factors regulating oxidative
108 energy processes, with a concomitant increase in the activity of glycolytic enzymes; and

109 ii) flywheel RE performed during bed rest would partly counteract such alterations. In
110 addition, both gene expression and activity of oxidative and glycolytic enzymes were
111 analyzed, allowing for an examination of the mechanisms controlling long-term,
112 unloading-induced metabolic alterations in human skeletal muscle.
113

114

115 **MATERIALS AND METHODS**

116 **General design**

117 Twenty one men (26-41 yr) were assigned to either bed rest with (BRE; n=9) or without
118 (BR; n=12) concurrent iso-inertial RE (4 sets of 7 maximal concentric-eccentric
119 repetitions every third day) for the quadriceps muscle employing flywheel technology.
120 Muscle biopsies from m. vastus lateralis were obtained from all subjects before bed rest
121 and prior to reambulation. Activity and mRNA content of enzymes controlling aerobic
122 and anaerobic glucose metabolism were assessed; i.e. CS, PFK-1, glycogen synthase
123 (GS), glycogen phosphorylase (GPh), and hexokinase (HK). In addition, gene
124 expression of succinate dehydrogenase (SDH) subunits (A, B, C, D), PGC-1 α , VEGF
125 and myostatin was also evaluated.

126

127 **Subjects**

128 Potential candidates were interviewed by trained personnel from the Institute for Space
129 Medicine and Physiology (MEDES) clinic, where the study was carried out. After a
130 general physical examination, twenty one healthy men were recruited and assigned to
131 either 90 days of head-down tilt bed rest with (BRE; n=9, 33 \pm 5 yr, 176 \pm 5 cm, and 71 \pm 6
132 kg) or without (BR; n=12, 32 \pm 4 yr, 173 \pm 3 cm, and 72 \pm 5 kg) concurrent flywheel RE.
133 Subjects were informed of the purposes, risks and premises associated with the study
134 before written consent for participation was obtained. The study was conducted in
135 accordance with the declaration of Helsinki, and protocols were approved by the local
136 Ethical Committee in Toulouse (*le Comité Consultative de Protection des Personnes*
137 *dans la Recherche Biomédicale de Toulouse I*).

138

139 **Head-down tilt bed rest**

140 Subjects were subjected to 6° head-down tilt position at all times (i.e. rest, shower,
141 transportation, exercise training, toilet procedures). Yet, participants were allowed to
142 perform movements in the horizontal plane and to rest on their elbows during meals.
143 Actions to ensure compliance included video surveillance and pressure-sensitive
144 mattresses. Massages and ankle circumduction movements were performed on a daily
145 basis by physiotherapists.

146

147 **Flywheel resistance exercise**

148 The BRE group performed flywheel RE employing the supine (6° head-down tilt) squat
149 exercise mode every third day (2-3 days per week), beginning on day 5 of bed rest. Each
150 exercise session consisted of 4 sets of 7 maximal concentric-eccentric repetitions, with a
151 recovery time of 2 min between sets. Joint angular velocity, joint angles, force, work
152 and power were measured for each repetition (3).

153

154 **Skeletal muscle biopsies**

155 Muscle biopsies were obtained from the mid portion of the m. vastus lateralis of the
156 dominant leg in all subjects before bed rest (PRE), and prior to reambulation at day 84
157 of bed rest (POST). Although the bed rest period lasted 90 days, POST biopsy samples
158 were collected at day 84 to avoid any potential interference of multiple testing
159 procedures during the last 5 days of the bed rest intervention. Under local anesthesia, 5-
160 mm Bergström-needles (6) were used to obtain muscle tissue samples that were
161 immediately cleansed of excess blood, fat, and connective tissue before being frozen in
162 liquid nitrogen at -80°C.

163

164 **Enzymatic activity**

165 About 10 mg of muscle tissue per sample was homogenized in 30 volumes of ice-
166 cooled extraction medium (50 mM HCl-Tris, 4 mM EDTA, 50 mM KF, 30 mM β -
167 mercatoethanol, pH 7) and centrifuged at 15,000 g at 4°C for 15 min. Then, enzymatic
168 activities were measured immediately in the supernatant. GS and GPh were measured
169 by radioactive methods (22). HK (total), PFK-1 and CS were determined by
170 spectrophotometry as previously described (36). Total protein concentration was
171 measured using Bradford's technique (7) to express the enzymatic activity as mU/mg of
172 protein.

173

174 **RNA isolation, reverse transcription, and real-time PCR**

175 Total RNA from muscle tissue samples (~20 mg wet weight) was extracted using
176 TRIZOL[®] (Invitrogen Life Technologies, Carlsbad, CA). Reverse transcription into
177 cDNA was performed on 1 μ g of total RNA from each sample following the
178 instructions of a commercial kit (High Capacity Reverse Transcription Kit, Applied
179 Biosystems, Foster City, CA). Real-time polymerase chain reaction (PCR) was used to
180 measure specific mRNAs (ABI-PRISMA 7700 Sequence Detector, Perkin-Elmer
181 Applied Biosystems). TaqMan[®] primers and probes for myostatin (Hs00193363_m1),
182 PGC-1 α (Hs01016724_m1), VEGF (Hs99999070_m1) and PFK (Hs00175997_m1)
183 were derived from the TaqMan[®] Gene Expression Assays (Applied Biosystems). Roche
184 Universal probe library guidelines were followed to design the amplicons for SDH
185 subunits A, B, C, and D genes, using short hydrolysis probes: HK-2 (HK-2; UPL#69,
186 CATTGTTGCCAAGCGTCTACA, CTTTGCCACTGCCATCCT); CS (CS; UPL#66,
187 TCCGACCCTTACCTGTCCTT, ACTTCCTGATTTGCCAGTCC); GS (GYS1;
188 UPL#2 2, TATGAGCCTTGGGGCTACAC, GGTCTGCGATGTGTTCCTC); GPh

189 (PYGM; UPL#87, CTCGTGTCCTGTACCCCAAT, TTGAAGCGACGGATGATGT);
190 SDH A (SDHA UPL#5. ATTTGGTGGACAGAGCCTCA,
191 CTGGTATCATATCGCAGAGACCT); SDH B (SDHB; UPL#5,
192 GGTCGCCCTCTCCTTGAG, GATGGCAAATTTCTTGATACGG); SDH C (SDHC;
193 UPL#57, TGGAAGTTGTGAAGTCCCTGT, TTTTCCTAGGTCCCACATCAA); SDH
194 D (SDHD; UPL#57, CAGCCCTCACTCTTCATGGT,
195 AGCTTTCTGCAAGGCATCC). Amplification mixes (10 µl) contained the diluted
196 (1:100) cDNA sample (4.5 µl), 2x TaqMan[®] Fast Universal PCR Master Mix (5.0 µl)
197 and specific primers (0.5 µl). Reactions performed with Roche Universal probe library
198 consisted of 10µl 2X Lightcycler 480 probes mastermix (Roche #4707494001), 0.2µl
199 corresponding probe 100X, 1µl of each primer 10µM, 5 µl of the diluted cDNA sample
200 and PCR-grade water to 20µl. Thermal cycling protocol employed consisted of 2 min at
201 50°C and 10 min at 90°C followed by 40 cycles at 95°C for 15 s and 60°C for 1 min.
202 Gene expression levels were determined using the 2- $\Delta\Delta$ CT method (26, 39). Any
203 potential variation in RNA loading and quantification was corrected by employing 18S
204 rRNA (UPL#66, ATCCATTGGAGGGCAAGTC, GCTCCCAAGATCCAACTACG;
205 TaqMan[®], Hs01375212_g1) as an endogenous control. Glyceraldehyde phosphate
206 dehydrogenase (GAPDH, Roche GAPD gene assay #05190541001; TaqMan[®],
207 Hs99999905_m1) was analyzed as a secondary endogenous control gene. Results were
208 almost identical for 18S and GAPDH such that the GAPDH/18S ratio did not vary.

209

210 **Data Analysis**

211 A one way ANOVA was applied to each of the four groups of samples: PRE BR vs.
212 PRE BRE; PRE BR vs. POST BR; PRE BRE vs. POST BRE; POST BR vs. POST
213 BRE. To directly compare BR and BRE sets of samples, the increment non-dimensional

214 ratio $INC = ([post_value]-[pre_value])/[pre_value]$ was calculated for each variable.
215 One way ANOVA was applied to INC BR vs. INC BRE. In all ANOVA analyses,
216 Levene's Test for Equality of Variances was performed. Welch and Brown and
217 Forsythe tests were used when the assumption of homogeneity of variances was not
218 met. Discriminant analysis by Wilks stepping method was used to complement mean
219 comparisons by studying effectiveness of the 29 variables in distinguishing INC BR(13)
220 from INC BRE(10) and observing variability. Wilks Lambda measures the proportion
221 of the total variance not yet explained by a set of variables. It decreases from 1 at each
222 step when a new variable is selected until no further improvement is produced. Wilks
223 Lambda would be close to 0 at this moment. Pearson's correlation was calculated to
224 measure the degree of linear dependence among all INC variables in BR and BRE. The
225 significance level was set at 0.05. All statistical analyses were performed using SPSS
226 version 18 (SPSS Inc., Chicago, IL).

227

228 **Abbreviations:** PGC-1 α , peroxisome proliferator-activated receptor gamma
229 coactivator-1; VEGF, vascular endothelial growth factor; GS, glycogen synthase; GPh,
230 glycogen phosphorylase; HK-2, hexokinase-2; PFK-1, phosphofructokinase-1; CS,
231 citrate synthase; SDH A, succinate dehydrogenase a subunit; SDH B, succinate
232 dehydrogenase b subunit; SDH C, succinate dehydrogenase c subunit; SDH D,
233 succinate dehydrogenase d subunit; Micro-RNA, miRNA; BR, bed rest group; BRE,
234 bed-rest and flywheel resistance exercise group; RE, resistance exercise.

235

236 **RESULTS**

237 Briefly and as reported elsewhere in greater detailed (3), muscle volume of m.
238 quadriceps decreased by 18% in BR after the bed rest period, while no changes were
239 reported for BRE. Likewise, force and power decrements were much greater for BR
240 than BRE (3). In addition, single fiber analysis revealed reduced diameter, peak force
241 and specific force in myosin heavy chain (MHC) I fibers, and decreased peak force in
242 MHC IIa fibers in BR, but not BRE (55).

243

244 No significant differences between BR and BRE were found at PRE in activities or gene
245 expression levels, except for HK activity ($P = 0.03$). Given that characteristics of BR vs.
246 BRE did not differ in terms of sex, height and body mass, the difference found in HK at
247 PRE may be explained by a chance/random effect.

248

249 Bed rest triggered a general reduction in the activity in most of the enzymes analyzed
250 with a statistically significant decrease in the activity of HK ($P = 0.03$) and CS ($P =$
251 0.001) (Table 1). Although the exercise training performed by BRE induced an
252 increment in the activity of the majority of the enzymes evaluated (except CS activity),
253 statistically significant changes were only obtained for GPh ($P = 0.05$) (Table 1).
254 Analysis of pre-to-post change between BR vs. BRE (INC), showed activity of HK ($P =$
255 0.05) and GPh ($P = 0.006$) was significantly different across groups, indicating
256 increased activity in BRE (Table 1 and Fig.1A).

257

258 After the 84 d of bed rest, subjects from BR showed reduced gene expression of most of
259 the enzymes analyzed (HK-2; $P = 0.0001$, CS; $P < 0.0001$, SDHB, $P = 0.0001$, SDHC, P
260 $= 0.036$) (Table 2). However, mRNA levels of PFK increased after 84 d bed rest ($P =$

261 0.05). The flywheel RE training performed by BRE preserved gene expression of CS,
262 SDHB and SDHC, and attenuated the reduction in HK-2 mRNA levels. In addition, no
263 significant increase in PFK expression was found in BRE (Table 2). INC analysis of
264 PRE-to-POST change between BR vs. BRE, showed mRNA expression was
265 significantly different for HK-2 ($P = 0.045$), CS ($P = 0.02$) and SDHB ($P = 0.008$),
266 indicating smaller changes in BRE than BR after 84 d bed rest (Table 2 and Fig.1B).

267

268 A reduced gene expression of PGC-1 α and VEGF from PRE to POST was found in BR
269 ($P = 0.031$ and $P = 0.009$, respectively) and BRE ($P = 0.014$ and $P < 0.0001$,
270 respectively) (Table 2). Myostatin, a negative regulator of muscle mass, increased after
271 the 84 d of bed rest in BR ($P < 0.0001$), but decreased in BRE ($P = 0.011$). Analysis of
272 PRE-to-POST change between BR vs. BRE (INC), showed mRNA expression of VEGF
273 ($P = 0.04$) and myostatin ($P < 0.0001$) was different across groups, indicating a greater
274 reduction of both VEGF and myostatin in BRE (Table 2 and Fig. 1C).

275

276 Significant correlations among the activity of all the enzymes measured in BR were
277 identified (except PFK-1 vs. GPh, and PFK-1 vs. GS) (Table 3). Thus, Pearson's
278 correlation coefficient was in the range of 0.57-0.82 for all pairs analyzed. Likewise,
279 significant correlations were found between activity of all enzymes measured in BRE (r
280 values between 0.93-0.99), except in those correlations involving GPh activity.

281

282 The discriminant analysis by the Wilks stepwise method was used to further investigate
283 the relationships among outcomes measured. Myostatin, GPh (activity), GPh (mRNA),
284 SDHB (mRNA), SDHD (mRNA) and HK-2 (mRNA) were the variables explaining to a
285 greater extend the changes in BR vs. BRE. After each of the six steps, the Wilks

286 Lambdas were 1.00, 0.47, 0.35, 0.23, 0.18, 0.12 respectively, indicating a good
287 classifying result (Table 4). The inclusion of more steps and variables did not improve
288 the results.

289

290

291 **DISCUSSION**

292 This study examined the consequences of 84 d simulated microgravity on skeletal
293 muscle oxidative and glycolytic capacity, and the efficacy of flywheel RE to counteract
294 microgravity-induced metabolic alterations. Long-term head-down tilt bed rest induced
295 a decreased in the activity and/or gene expression of enzymes involved in oxidative
296 energy production (CS and SDH), along with a reduction in the gene expression of well-
297 known markers of aerobic capacity in humans (VEGF and PGC-1 α). In contrast,
298 glycolytic metabolism seemed to be maintained (GPh and PFK-1 activities) or slightly
299 increased (PFK-1 mRNA). Importantly, high-intensity, low-volume flywheel RE was
300 effective in offsetting some of the microgravity-induced metabolic alterations by
301 reducing the magnitude of oxidative deconditioning. The current experiments, assessing
302 both enzyme activity and gene expression, revealed that although mRNA changes partly
303 explain the unloading-induced alterations, enzymatic activity should be measured to
304 evaluate the real impact of microgravity on skeletal muscle metabolism. It follows that
305 different post-transcriptional regulatory mechanisms should be considered and studied
306 in future investigations.

307

308 HK is a key enzyme controlling the entry and phosphorylation of glucose in skeletal
309 muscle. Although muscle HK-1 is a constitutive enzyme, the vast majority of HK
310 activity in skeletal muscle is delivered by the HK-2 isoform, which is also the isoform
311 subjected to potential changes (41). Long-term bed rest induced a decrease in HK
312 activity, together with a reduction in HK-2 gene expression levels, likely reducing the
313 potential of the entire glucose energy system. These results contrast with previous
314 reports in rats showing microgravity-induced increments of HK activity (10, 30), which

315 highlights the difficulty of extrapolating conclusions from studies using animal models
316 to humans. Flywheel RE was effective in offsetting microgravity-induced HK activity
317 alterations, as well as reducing the impact of unloading in HK-2 gene expression.

318

319 CS and SDH, with two hydrophilic (A and B) and two hydrophobic (C and D) subunits,
320 are two of the most critical enzymes controlling oxidative energy production. The
321 results from the current study, showing decreased mRNA levels of SDHB and SDHC,
322 together with a reduction in CS activity and gene expression, extend previous findings
323 of decreased skeletal muscle oxidative potential after simulated microgravity (5, 14, 23,
324 43), and add novel information regarding oxidative metabolism alterations after long-
325 term microgravity exposure. In addition, 84 d bed rest triggered a reduction in the gene
326 expression of PGC-1 α and VEGF, key markers controlling mitochondrial biogenesis
327 (59) and angiogenesis (18), respectively. The reduced PGC-1 α and VEGF mRNA levels
328 are an additional indication of compromised aerobic capacity in skeletal muscle after
329 long-term bed rest. Our data contrast previous findings after short-term microgravity (2,
330 43), yet confirm results from more extended unloading studies (8,12). Flywheel RE
331 could not compensate the unloading-induced downregulation of PGC-1 α and VEGF in
332 the current investigation, contrasting previous reports of 5 wk unilateral lower limb
333 suspension (12). However, the current results do not rule out that expression of PGC-1 α
334 and/or VEGF could have been increased immediately after each RE bout (13, 27), yet
335 showing an overall decrease in the POST measurements. Indeed, this notion would help
336 explaining the preserved CS activity, and mRNA levels of CS, SDHB and SDHC in
337 BRE subjects. In addition, the apparent disparity in exercise-induced adaptations of
338 oxidative/aerobic molecular markers after bed rest may be explained by a slower or less
339 sensitive response of growth/transcriptional coactivators to exercise when compared

340 with oxidative enzymes, as suggested elsewhere (43). In any case, the results of the
341 current investigation seem to support the idea of an augmented muscle's responsiveness
342 to adapt during unloading (12), given that the RE program employed could maintained
343 the activity and expression of key oxidative enzymes even though it was not originally
344 designed to affect muscle oxidative potential.

345

346 In an attempt to compensate for the reduced oxidative metabolic capacity, the skeletal
347 muscle usually shows increased reliance upon glycolysis when subjected to 0-g (4, 12,
348 50). The current study expands this notion to long-term microgravity exposure, as
349 indicated by the increased PFK gene expression after 84 d bed rest. Of note however,
350 PFK activity, as well as GPh, which catalyze the rate-limiting step in the
351 glycogenolysis, remained unchanged after the bed rest period.

352

353 The current study, assessing both activity and gene expression levels on enzymes
354 controlling oxidative and glycolytic metabolism, allows for preliminary observations
355 regarding the mechanisms governing the metabolic changes induced by microgravity
356 with or without RE countermeasures. Thus, 84 d bed rest induced changes in mRNA
357 levels that were followed by the consequent, same-direction alteration in enzyme
358 activity (GS, HK and CS). Yet, PFK gene expression increased significantly, while their
359 activity tended to decreased after bed rest. The relationships between activity vs. gene
360 expression seems to be altered by the RE protocol, where a mismatch in these outcome
361 measurements was found for GS and HK. A potential explanation for these divergences
362 is a different time course of gene expression vs. enzyme activity. The results suggest
363 that activities of both GS and HK may be specifically degraded during immobilization
364 or that mRNAs are less stable than proteins (57). Indeed, such effect has been described

365 for HK, where increased mRNA preceded any change on HK activity before returning
366 to basal levels (22, 35). In addition, changes in enzyme activity upon microgravity
367 and/or exercise may be dependent on post-transcriptional regulatory mechanisms (i.e.
368 microRNAs). microRNAs are single-stranded and short RNA molecules that bind to
369 their specific mRNA target repressing its corresponding protein expression, with a
370 significant role in exercise-induced muscle adaptations (47). Clearly, there is a need for
371 studies investigating the potential role of microRNAs in metabolic alterations under 0-g
372 conditions. In any case, it appears that to evaluate metabolic alterations to microgravity
373 with and without concurrent exercise protocols, gene expression analysis may not be
374 accurate enough, making the assessment of end-point enzyme activity adaptations,
375 necessary.

376

377 The correlation analysis performed in the current study revealed that microgravity-
378 induced alterations in the metabolic systems of skeletal muscle are highly coordinated.
379 Likewise, the impact of flywheel RE on oxidative and glycolytic capacity seems to be
380 tightly harmonized, with the exception of GPh activity. Indeed, it appears that, for
381 unknown reasons, GPh over-responds to flywheel RE when compared with the activity
382 of other enzymes analyzed. In addition, our statistical approach indicated that changes
383 in myostatin were the most powerful variable differentiating BR from BRE subjects, i.e.
384 effect of the exercise countermeasure. This is not surprising, given that myostatin is a
385 negative master regulator of muscle mass, and the differences in muscle size adaptations
386 were very significant across groups in the present sample due to the exercise paradigm
387 employed (3). Yet, several metabolic markers (GPh activity and gene expression, and
388 mRNA levels of SDHB, SDHD and HK-2) also help to identify the effect of the
389 exercise countermeasure proposed.

390 Furthermore from the prominent role of myostatin in muscle mass regulation, there is an
391 extensive amount of evidence relating myostatin and muscle energetic metabolism.
392 Exposure of muscle to β 2-adrenergic stimulation, a hypertrophic stimulus, modifies
393 expression levels of several genes associated with myostatin signaling, attenuating its
394 effects, while enhancing HK-2 expression in muscle (38). Furthermore, *in-silico*
395 analysis of the promotor regions of HK-2, SDH B and myostatin genes using the
396 PROMO algorithm (31) revealed several common putative transcription factors binding
397 sites, including glucocorticoid receptor motive. Interestingly, glucocorticoids in skeletal
398 muscle induce protein degradation, likely involving myostatin, while attenuating insulin
399 signaling (24), which regulates HK-2 expression (58). Moreover, myostatin enhances
400 glycolysis via AMPK activation (9). Likewise, near total ablation of myostatin signaling
401 caused by genetic depletion or specific signaling blockade (49, 40, 32, 42) elicits a
402 decrease in oxidative metabolism. In contrast, a modest decrease of myostatin signaling
403 enhances oxidative metabolism (34), as was also observed in response to aerobic
404 exercise (21). Although the mechanism(s) relating myostatin and metabolic enzymes
405 expression is not well understood, the evidence supports a role of myostatin in the
406 regulation of energy metabolism, either directly or indirectly. Therefore, future studies
407 should insure the potential role of myostatin as a valuable biomarker to evaluate the
408 effect of a particular exercise paradigm or disuse condition on skeletal muscle,
409 including both muscle mass and the oxidative capacity in the muscle.

410 More systematic research is needed to elucidate whether flywheel RE could be a
411 realistic model to prevent skeletal muscle metabolic alterations in a 0-g environment.
412 While results from the current investigation indicate this may be partly true, it is
413 unlikely this RE model would succeed in counteracting spaceflight cardiovascular
414 deconditioning (25, 56). To this end, our group has developed and validated both

415 exercise tools and protocols using iso-inertial flywheel technology (11, 13, 28, 29, 52),
416 which allow for both resistance and cardiovascular exercise, to meet operational aspects
417 of serving future long-term, interplanetary space missions.

418

419 In conclusion, this study demonstrated that 84 d microgravity exposure compromise
420 skeletal muscle oxidative potential by reducing the activity and/or gene expression of
421 master regulators of aerobic metabolism, i.e. CS, SDH, and PGC-1 α . In contrast,
422 glycolytic capacity was essentially unaltered (GPh, PFK). As we hypothesized, high-
423 intensity, low-volume flywheel RE was effective in counteracting some, but not all,
424 unloading-induced metabolic alterations. Thus, it appears other exercise paradigms,
425 most likely combining aerobic and resistance exercise, should be used for complete
426 protection against microgravity-induced skeletal muscle alterations. Additionally, our
427 experiments indicate that the regulation of muscle metabolic function is rather complex,
428 with several potential post-transcriptional mechanisms involved in the final end-point
429 adaptations (i.e. enzymatic activity). This novel information advances our
430 understanding to enhance in-flight exercise hardware and protocols for future long-haul
431 space missions.

432

433 **Acknowledgements**

434 This study was supported by grants from the European Space Agency (MAP project
435 AO-2004-032; PAT and RC) and the Swedish National Space Board (PAT). We thank
436 the volunteers who endured the long-term bed rest. The technical support from the staff
437 at MEDES and the Ranguel Hospital is greatly acknowledged. The authors also thank
438 Dr. José Luis Solanas (AMBITT S.L.) for statistical support. Present address of Paula

439 Rodriguez Mingualez: Georgia Prevention Institute, Department of Pediatrics, Augusta

440 University, Augusta, Georgia, USA

441

442 **References**

- 443 1. **Adams GR, Caiozzo VJ, and Baldwin KM.** Skeletal muscle unweighting:
444 spaceflight and ground-based models. *J Appl Physiol* 95: 2185-2201, 2003.
- 445 2. **Alibegovic AC, Sonne MP, Hojbjerg L, Bork-Jensen J, Jacobsen S, Nilsson E,**
446 **Faerch K, Hiscock N, Mortensen B, Friedrichsen M, Stallknecht B, Dela F, and**
447 **Vaag A.** Insulin resistance induced by physical inactivity is associated with multiple
448 transcriptional changes in skeletal muscle in young men. *Am J Physiol Endocrinol*
449 *Metab* 299: E752-763, 2010.
- 450 3. **Alkner BA, and Tesch PA.** Knee extensor and plantar flexor muscle size and
451 function following 90 days of bed rest with or without resistance exercise. *Eur J Appl*
452 *Physiol* 93: 294-305, 2004.
- 453 4. **Baldwin KM, Herrick RE, and McCue SA.** Substrate oxidation capacity in rodent
454 skeletal muscle: effects of exposure to zero gravity. *J Appl Physiol* 75: 2466-2470,
455 1993.
- 456 5. **Berg HE, Dudley GA, Hather B, and Tesch PA.** Work capacity and metabolic and
457 morphologic characteristics of the human quadriceps muscle in response to unloading.
458 *Clin Physiol* 13: 337-347, 1993.
- 459 6. **Bergstrom J.** Muscle Electrolytes in Man. *Scand J Clin Lab Invest* 14: 511-513,
460 1962.
- 461 7. **Bradford MM.** A rapid and sensitive method for the quantitation of microgram
462 quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72:
463 248-254, 1976.
- 464 8. **Brocca L, Cannavino J, Coletto L, Biolo G, Sandri M, Bottinelli R, and**
465 **Pellegrino MA.** The time course of the adaptations of human muscle proteome to bed
466 rest and the underlying mechanisms. *J Physiol* 590: 5211-5230, 2012.

- 467 9. **Chen Y, Ye J Cao L, Zhang Y, Xia W and Zhu D.** Myostatin regulates glucose
468 metabolism via the AMP-activated protein kinase pathway in skeletal muscle cells. *Int.*
469 *J. Biochem. Cell Biol.* 42: 2072-81, 2010.
- 470 10. **Chi MM, Choksi R, Nemeth P, Krasnov I, Ilyina-Kakueva E, Manchester JK,**
471 **and Lowry OH.** Effects of microgravity and tail suspension on enzymes of individual
472 soleus and tibialis anterior fibers. *J Appl Physiol* 73: 66S-73S, 1992.
- 473 11. **Cotter JA, Yu A, Haddad F, Kreitenberg A, Baker MJ, Tesch PA, Baldwin**
474 **KM, Caiozzo VJ, and Adams GR.** Concurrent exercise on a gravity-independent
475 device during simulated microgravity. *Med Sci Sports Exerc* 47: 990-1000, 2015.
- 476 12. **Fernandez-Gonzalo R, Irimia JM, Cusso R, Gustafsson T, Linne A, and Tesch**
477 **PA.** Flywheel resistance exercise to maintain muscle oxidative potential during
478 unloading. *Aviat Space Environ Med* 85: 694-699, 2014.
- 479 13. **Fernandez-Gonzalo R, Lundberg TR, and Tesch PA.** Acute molecular responses
480 in untrained and trained muscle subjected to aerobic and resistance exercise training
481 versus resistance training alone. *Acta Physiol (Oxf)* In Review: 2013.
- 482 14. **Ferretti G, Antonutto G, Denis C, Hoppeler H, Minetti AE, Narici MV, and**
483 **Desplanches D.** The interplay of central and peripheral factors in limiting maximal O₂
484 consumption in man after prolonged bed rest. *J Physiol* 501 (Pt 3): 677-686, 1997.
- 485 15. **Gallagher P, Trappe S, Harber M, Creer A, Mazzetti S, Trappe T, Alkner B,**
486 **and Tesch P.** Effects of 84-days of bedrest and resistance training on single muscle
487 fibre myosin heavy chain distribution in human vastus lateralis and soleus muscles. *Acta*
488 *Physiol Scand* 185: 61-69, 2005.
- 489 16. **Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM,**
490 **Nieman DC, and Swain DP.** American College of Sports Medicine position stand.
491 Quantity and quality of exercise for developing and maintaining cardiorespiratory,

492 musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for
493 prescribing exercise. *Med Sci Sports Exerc* 43: 1334-1359, 2011.

494 17. **Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O, and McPherron AC.**
495 Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves
496 insulin sensitivity. *PLoS One* 4:e4937. DOI:10.1371, 2009.

497 18. **Gustafsson T.** Vascular remodelling in human skeletal muscle. *Biochem Soc Trans*
498 39: 1628-1632, 2011.

499 19. **Hackney KJ, and Ploutz-Snyder LL.** Unilateral lower limb suspension: integrative
500 physiological knowledge from the past 20 years (1991-2011). *Eur J Appl Physiol* 112:
501 9-22, 2012.

502 20. **Hikida RS, Gollnick PD, Dudley GA, Convertino VA, and Buchanan P.**
503 Structural and metabolic characteristics of human skeletal muscle following 30 days of
504 simulated microgravity. *Aviat Space Environ Med* 60: 664-670, 1989.

505 21. **Hittel DS, Axelson M, Sarna N, Shearer J, Huffman KM and Kraus WE.**
506 Myostatin decreases with aerobic exercise and associates with insulin resistance. *Med*
507 *Sci Sports Exerc.* 42(11):2023-9, 2010.

508 22. **Irimia JM, Rovira J, Nielsen JN, Guerrero M, Wojtaszewski JF, and Cusso R.**
509 Hexokinase 2, glycogen synthase and phosphorylase play a key role in muscle glycogen
510 supercompensation. *PLoS One* 7: e42453, 2012.

511 23. **Krainski F, Hastings JL, Heinicke K, Romain N, Pacini EL, Snell PG, Wyrick**
512 **P, Palmer MD, Haller RG, and Levine BD.** The effect of rowing ergometry and
513 resistive exercise on skeletal muscle structure and function during bed rest. *J Appl*
514 *Physiol* 116: 1569-1581, 2014.

515 24. **Kuo T, Harris CA and Wang JC.** Metabolic functions of glucocorticoid receptor
516 in skeletal muscle. *Mol Cell Endocrinol* 380: 79–88, 2013.

517

518 25. **Levine BD, Lane LD, Watenpaugh DE, Gaffney FA, Buckey JC, and Blomqvist**

519 **CG.** Maximal exercise performance after adaptation to microgravity. *J Appl Physiol* 81:

520 686-694, 1996.

521 26. **Livak KJ, and Schmittgen TD.** Analysis of relative gene expression data using

522 real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25: 402-408,

523 2001.

524 27. **Lundberg TR, Fernandez-Gonzalo R, Gustafsson T, and Tesch PA.** Aerobic

525 Exercise Alters Skeletal Muscle Molecular Responses to Resistance Exercise. *Med Sci*

526 *Sports Exerc* 44: 1680-1688, 2012.

527 28. **Lundberg TR, Fernandez-Gonzalo R, Gustafsson T, and Tesch PA.** Aerobic

528 exercise does not compromise muscle hypertrophy response to short-term resistance

529 training. *J Appl Physiol* 114: 81-89, 2013.

530 29. **Lundberg TR, Fernandez-Gonzalo R, and Tesch PA.** Exercise-induced AMPK

531 activation does not interfere with muscle hypertrophy in response to resistance training

532 in men. *J Appl Physiol* 116: 611-620, 2014.

533 30. **Manchester JK, Chi MM, Norris B, Ferrier B, Krasnov I, Nemeth PM,**

534 **McDougal DB, Jr. and Lowry OH.** Effect of microgravity on metabolic enzymes of

535 individual muscle fibers. *FASEB J* 4: 55-63, 1990.

536 31. **Messeguer X, Escudero R, Farré D, Núñez O, Martínez J and Albà M.M.**

537 **PROMO:** detection of known transcription regulator y elements using species-tailored

538 searches. *Bioinformatics* 18 (2): 333-334, 2002.

539 32. **Mouisel E, Relizani K, Mille-Hamard L, Denis R, Hourdé C, Agbulut O, Patel**

540 **K, Arandel L, Morales-Gonzalez S, Vignaud A, Garcia L, Ferry A, Luquet S,**

541 **Billat V, Ventura-Clapier R, Schuelke M and Amthor H.** Myostatin is a key

542 mediator between energy metabolism and endurance capacity of skeletal muscle. *Am J*
543 *Physiol Regul Integr Comp Physiol*. 2014 307(4):R444-54.

544 33. **Moore AD, Jr., Downs ME, Lee SM, Feiveson AH, Knudsen P, and Ploutz-**
545 **Snyder L.** Peak exercise oxygen uptake during and following long-duration spaceflight.
546 *J Appl Physiol* 117: 231-238, 2014.

547 34. **Murphy KT, Koopman R, Naim T, Léger B, Trieu J, Ibebunjo C and Lynch**
548 **GS.** Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for
549 myostatin signaling in skeletal muscle structure and function. *FASEB J*. 24:4433-4442,
550 2010.

551 35. **O'Doherty RM, Bracy DP, Osawa H, Wasserman DH, and Graner DK.** Rat
552 skeletal muscle hexokinase II mRNA and activity are increased by a single bout of acute
553 exercise. *Am J Physiol* 266: E171-178, 1994.

554 36. **Parra J, Cadefau JA, Rodas G, Amigo N, and Cusso R.** The distribution of rest
555 periods affects performance and adaptations of energy metabolism induced by high-
556 intensity training in human muscle. *Acta Physiol Scand* 169: 157-165, 2000.

557 37. **Pavy-Le Traon A, Heer M, Narici MV, Rittweger J, and Vernikos J.** From
558 space to Earth: advances in human physiology from 20 years of bed rest studies (1986-
559 2006). *Eur J Appl Physiol* 101: 143-194, 2007.

560 38. **Pearen MA, Ryall JG, Lynch GS, and Muscat GO.** Expression profiling of
561 skeletal muscle following acute and chronic β_2 -adrenergic stimulation: implications for
562 hypertrophy, metabolism and circadian rhythm. *BMC Genomics* 10:448 DOI:
563 10.1186/1471-2164-10-448, 2009.

564 39. **Pfaffl MW.** A new mathematical model for relative quantification in real-time RT-
565 PCR. *Nucleic Acids Res* 29: e45, 2001.

566 40. **Ploquin C, Chabi B, Fouret G, Vernus B, Feillet-Coudray C, Coudray C,**
567 **Bonnieu A, and Ramonatxo C.** Lack of myostatin alters intermyofibrillar
568 mitochondria activity, unbalances redox status, and impairs tolerance to chronic
569 repetitive contractions in muscle. *Am. J. Physiol Endocrinol Metab* 302: E1000-1008,
570 2012.

571 41. **Printz RL, Koch S, Potter LR, O'Doherty RM, Tiesinga JJ, Moritz S, and**
572 **Granner DK.** Hexokinase II mRNA and gene structure, regulation by insulin, and
573 evolution. *J Biol Chem* 268: 5209-5219, 1993.

574 42. **Rahimov F, King OD, Warsing LC, Powell RE, Emerson CP, Kunkel LM, and**
575 **Wagner KR.** Gene expression profiling of skeletal muscles treated with a soluble
576 activin type IIB receptor. *Physiol Genomics*, 43: 398-407, 2011.

577 43. **Ringholm S, Bienso RS, Küllerich K, Guadalupe-Grau A, Aachmann-Andersen**
578 **NJ, Saltin B, Plomgaard P, Lundby C, Wojtaszewski JF, Calbet JA, and Pilegaard**
579 **H.** Bed rest reduces metabolic protein content and abolishes exercise-induced mRNA
580 responses in human skeletal muscle. *Am J Physiol Endocrinol Metab* 301: E649-658,
581 2011.

582 44. **Rittweger J, Felsenberg D, Maganaris C, and Ferretti JL.** Vertical jump
583 performance after 90 days bed rest with and without flywheel resistive exercise,
584 including a 180 days follow-up. *Eur J Appl Physiol* 100: 427-436, 2007.

585 45. **Rittweger J, Frost HM, Schiessl H, Ohshima H, Alkner B, Tesch P, and**
586 **Felsenberg D.** Muscle atrophy and bone loss after 90 days' bed rest and the effects of
587 flywheel resistive exercise and pamidronate: results from the LTBR study. *Bone* 36:
588 1019-1029, 2005.

589 46. **Roy RR, Baldwin KM, and Edgerton VR.** The plasticity of skeletal muscle:
590 effects of neuromuscular activity. *Exerc Sport Sci Rev* 19: 269-312, 1991.

591 47. **Russell AP, and Lamon S.** Exercise, Skeletal Muscle and Circulating microRNAs.
592 *Progress in molecular biology and translational science* 135: 471-496, 2015.

593 48. **Schneider SM, Amonette WE, Blazine K, Bentley J, Lee SM, Loehr JA, Moore**
594 **AD, Jr., Rapley M, Mulder ER, and Smith SM.** Training with the International Space
595 Station interim resistive exercise device. *Med Sci Sports Exerc* 35: 1935-1945, 2003.

596 49. **Steelman CA, Recknor JC, Nettleton D, and Reecy JM.** Transcriptional profiling
597 of myostatin-knockout mice implicates Wnt signaling in postnatal skeletal muscle
598 growth and hypertrophy. *FASEB J.* **20(3): 580-582, 2006.**

599 50. **Stein TP, and Wade CE.** Metabolic consequences of muscle disuse atrophy. *J Nutr*
600 135: 1824S-1828S, 2005.

601 51. **Tesch PA, Lundberg TR, and Fernandez Gonzalo R.** Unilateral lower limb
602 suspension (ULLS): from subject selection to "omic" responses. *J Appl Physiol* jap
603 01052 02015, 2016.

604 52. **Tesch PA, Pozzo M, Ainegren M, Swaren M, and Linnehan RM.** Cardiovascular
605 responses to rowing on a novel ergometer designed for both resistance and aerobic
606 training in space. *Aviat Space Environ Med* 84: 516-521, 2013.

607 53. **Tesch PA, Trieschmann JT, and Ekberg A.** Hypertrophy of chronically unloaded
608 muscle subjected to resistance exercise. *J Appl Physiol* 96: 1451-1458, 2004.

609 54. **Trappe S, Costill D, Gallagher P, Creer A, Peters JR, Evans H, Riley DA, and**
610 **Fitts RH.** Exercise in space: human skeletal muscle after 6 months aboard the
611 International Space Station. *J Appl Physiol* 106: 1159-1168, 2009.

612 55. **Trappe S, Trappe T, Gallagher P, Harber M, Alkner B, and Tesch P.** Human
613 single muscle fibre function with 84 day bed-rest and resistance exercise. *J Physiol* 557:
614 501-513, 2004.

615 **56. Trappe T, Trappe S, Lee G, Widrick J, Fitts R, and Costill D.** Cardiorespiratory
616 responses to physical work during and following 17 days of bed rest and spaceflight. *J*
617 *Appl Physiol* 100: 951-957, 2006.

618 **57. Vogel C, and Marcotte EM.** Insights into the regulation of protein abundance from
619 proteomic and transcriptomic analyses. *Nature reviews Genetics* 13: 227-232, 2012.

620 **58. Vogt C, Ardehali H, Iozzo P, H. Jarvinen Yki, Koval J, Maezono K,**
621 **Pendergrass M, Printz R, Granner D, DeFronzo R, and Mandarin L.** Regulation of
622 hexokinase II expression in human skeletal muscle in vivo. *Metabolism* 49: 814-818,
623 2000.

624 **59. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A,**
625 **Cinti S, Lowell B, Scarpulla RC, and Spiegelman BM.** Mechanisms controlling
626 mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1.
627 *Cell* 98: 115-124, 1999.

628

629

630

631

632

633

634

635

636



637

638

639

640 **Figure Captions**

641

642 **Figure 1.** Non-dimensional ratio ($INC = ([post_value] - [pre_value]) / [pre_value]$) of
643 A, enzyme activity; B, gene expression (mRNA) of enzymes; and C, gene expression of
644 growth factors and transcriptional coactivators, for BR (84 d bed rest, grey bars, )
645 and BRE (84 d bed rest with flywheel resistance exercise, black bars, ) . CS; citrate
646 synthase, PFK; phosphofructokinase, HK; hexokinase, GPh; glycogen phosphorylase,
647 GS; glycogen synthase, SDH A; succinate dehydrogenase a subunit, SDH B; succinate
648 dehydrogenase b subunit, SDH C; succinate dehydrogenase c subunit, SDH D;
649 succinate dehydrogenase d subunit, VEGF; vascular endothelial growth factor, PGC-1 α ;
650 peroxisome proliferator-activated receptor gamma coactivator-1. *: denotes BR vs BRE
651 difference at P < 0.05 level; ***: denotes BR vs. BRE difference at P < 0.001 level.

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667 **TABLES**

668

Table 1. Enzymatic activities of subjects undergoing 84 d bed rest with (BRE; n = 9) or without (BR; n = 12) flywheel resistance exercise.

	PRE	POST	P (PRE-POST)	INC	P (INC_BR vs INC_BRE)
Glycogen synthase					
BR	23.6 ± 12.2	17.7 ± 9.6	0.20	-0.14	0.14
BRE	18.8 ± 10.0	23.4 ± 9.5	0.33	0.60	
Glycogen phosphorylase					
BR	265.4 ± 173.2	254.1 ± 164.7	0.87	-0.02	0.006***
BRE	205.1 ± 91.7	301.7 ± 121.3	0.05*	0.54	
Hexokinase					
BR	13.3 ± 3.3	10.6 ± 2.0	0.027*	-0.17	0.05*
BRE	8.6 ± 3.9	10.6 ± 4.4	0.33	0.43	
Phosphofructokinase					
BR	638.4 ± 209.2	598.2 ± 163.6	0.60	0.01	0.17
BRE	449.5 ± 245.4	555.7 ± 230.4	0.35	0.66	
Citrate synthase					
BR	84.8 ± 17.1	60.34 ± 15.1	0.0012***	-0.27	0.24
BRE	69.8 ± 41.4	60.07 ± 26.6	0.56	0.21	

Activities are expressed as mU/mg of protein. Values are means ± SD. *, P < 0.05, **, P < 0.01, ***, P < 0.001.

669

670

671

672

673

674

Table 2. Gene expression (mRNA) of selected enzymes and growth/transcriptional factors of subjects undergoing 84 d bed rest with (BRE; n = 9) or without (BR; n = 12) flywheel resistance exercise.

	PRE	POST	P (PRE-POST)	INC	P (INC_BR vs INC_BRE)
Glycogen synthase					
BR	20.04 ± 5.7	17.28 ± 4.5	0.20	-0.09	0.46
BRE	18.24 ± 4.0	17.35 ± 4.0	0.64	0.01	
Glycogen phosphorylase					
BR	52.82 ± 11.4	53.8 ± 22.7	0.89	0.06	0.32
BRE	50.52 ± 16.8	59.87 ± 18.2	0.27	0.24	
Hexokinase 2					
BR	8.99 ± 3.7	3.37 ± 2.0	0.0001***	-0.60	0.045*
BRE	9.02 ± 2.6	5.10 ± 1.3	0.001***	-0.41	
Phosphofructokinase					
BR	47.47 ± 10.	59.98 ± 18.5	0.050*	0.32	0.94
BRE	43.48 ± 11.7	55.28 ± 15.2	0.08	0.34	
Citrate synthase					
BR	69.01 ± 15.7	43.33 ± 8.5	< 0.00001***	-0.33	0.02*
BRE	63.17 ± 12.9	61.47 ± 13.6	0.078	0.005	
SDH A					
BR	24.21 ± 5.9	20.13 ± 5.3	0.09	-0.14	0.61
BRE	21.89 ± 5.3	19.82 ± 6.2	0.5	-0.09	
SDH B					
BR	12.21 ± 2.3	7.63 ± 2.5	0.0001***	-0.35	0.008***
BRE	11.22 ± 2.1	10.24 ± 1.5	0.28	-0.06	
SDH C					
BR	37.03 ± 8.6	28.52 ± 9.9	0.036*	-0.19	0.20
BRE	33.10 ± 6.9	31.50 ± 6.7	0.62	-0.02	
SDH D					
BR	22.08 ± 4.0	18.24 ± 5.6	0.069	-0.15	0.21
BRE	19.48 ± 3.5	18.97 ± 3.6	0.76	0.00	

PGC-1 α					
BR	0.82 \pm 0.23	0.62 \pm 0.25	0.031*	-0,18	0.14
BRE	0.78 \pm 0.19	0.51 \pm 0.10	0.014*	-0,32	
VEGF					
BR	2.90 \pm 0.61	2.15 \pm 1.13	0.009**	-0.26	0.04*
BRE	3.13 \pm 1.08	1.66 \pm 0.53	< 0.0001***	-0.45	
Myostatin					
BR	0.22 \pm 0.09	0.52 \pm 0.18	< 0.0001***	1.66	0.000***
BRE	0.22 \pm 0.07	0.14 \pm 0.04	0.011**	-0.32	

Gene expression levels are expressed as arbitrary units. Values are means \pm SD. SDH A; succinate dehydrogenase a subunit, SDH B; succinate dehydrogenase b subunit, SDH C; succinate dehydrogenase c subunit, SDH D; succinate dehydrogenase d subunit, PGC-1 α ; peroxisome proliferator-activated receptor gamma coactivator-1, VEGF; vascular endothelial growth factor. *, P < 0.05, **, P < 0.01, ***, P < 0.001.

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

Table 3. Pearson's correlation coefficient (r) of relative changes from PRE to POST in enzyme activity of subjects undergoing 84 d bed rest with (BRE; n = 9) or without (BR; n = 12) flywheel resistance exercise.

	BR	BRE
GS vs. GPh	0.68*	0.55
GS vs. HK	0.77**	0.95**
GS vs. PFK-1	0.56	0.93**
GS vs. CS	0.57*	0.94**
GPh vs. HK	0.65*	0.59
GPh vs. PFK-1	0.54	0.67
GPh vs. CS	0.79**	0.62
HK vs. PFK-1	0.75*	0.99**
HK vs. CS	0.73**	0.99**
PFK-1 vs. CS	0.82**	0.99**

GS; glycogen synthase, GPh; glycogen phosphorylase, HK; hexokinase, PFK-1; phosphofructokinase, CS; citrate synthase. *, P < 0.05, **, P < 0.01.

693

694

695

696

697

698

699

700

701

702

Table 4. Discriminant analysis by Wilks' Lambda method applied to the 703-dimensional ratio ($INC = ([post_value] - [pre_value]) / [pre_value]$). The right column shows the P value for the difference in INC across groups (i.e. 84 d bed rest vs. 84 d bed rest with resistance exercise).

	Step	1	2	3	4	5	6	P
Myostatin		1.00	0.68	0.67	0.51	0.31	0.22	< 0.0001***
GPh (activity)			0.47	0.46	0.34	0.23	0.22	0.006**
GPh (mRNA)				0.35	0.33	0.20	0.16	0.326
SDH B (mRNA)					0.23	0.22	0.18	0.008**
SDH D (mRNA)						0.18	0.15	0.854
HK-2 (mRNA)							0.12	0.046*

GPh; glycogen phosphorylase, SDH B; succinate dehydrogenase b subunit, SDH D; succinate dehydrogenase d subunit, HK-2; hexokinase 2. *; P < 0.05, **; P < 0.01, ***; P < 0.001.

704

705

706

707

708

709

710

711

712


713

714

715 **FIGURES**

716 **Figure 1.**


717 **A.**



718

719

720 **B.**



721


722

723

724

725

726 C.




727

728


FIGURES

Figure 1.


A.



B.



C.



TABLES

Table 1. Enzymatic activities of subjects undergoing 84 d bed rest with (BRE; n = 9) or without (BR; n = 12) flywheel resistance exercise.

	PRE	POST	P (PRE-POST)
Glycogen synthase			
BR	23.6 ± 12.2	17.7 ± 9.6	0.20
BRE	18.8 ± 10.0	23.4 ± 9.5	0.33
Glycogen Phosphorylase			
BR	265.4 ± 173.2	254.1 ± 164.7	0.87
BRE	205.1 ± 91.7	301.7 ± 121.3	0.05*
Hexokinase			
BR	13.3 ± 3.3	10.6 ± 2.0	0.027*
BRE	8.6 ± 3.9	10.6 ± 4.4	0.33
Phosphofructokinase-1			
BR	638.4 ± 209.2	598.2 ± 163.6	0.60
BRE	449.5 ± 245.4	555.7 ± 230.4	0.35
Citrate synthase			
BR	84.8 ± 17.1	60.34 ± 15.1	0.0012***
BRE	69.8 ± 41.4	60.07 ± 26.6	0.56

Activities are expressed as mU/mg of protein. Values are means ± SD. *, P < 0.05, **;

P < 0.01, ***, P < 0.001.

Table 2. Gene expression (mRNA) of selected enzymes and growth/transcriptional factors of subjects undergoing 84 d bed rest with (BRE; n = 9) or without (BR; n = 12) flywheel resistance exercise.

	PRE	POST	P (PRE-POST)
Glycogen synthase			
BR	20.04 ± 5.7	17.28 ± 4.5	0.20
BRE	18.24 ± 4.0	17.35 ± 4.0	0.64
Glycogen phosphorylase			
BR	52.82 ± 11.4	53.8 ± 22.7	0.89
BRE	50.52 ± 16.8	59.87 ± 18.2	0.27
Hexokinase-2			
BR	8.99 ± 3.7	3.37 ± 2.0	0.0001***
BRE	9.02 ± 2.6	5.10 ± 1.3	0.001***
Phosphofructokinase-1			
BR	47.47 ± 10.	59.98 ± 18.5	0.050*
BRE	43.48 ± 11.7	55.28 ± 15.2	0.08
Citrate synthase			
BR	69.01 ± 15.7	43.33 ± 8.5	< 0.00001***
BRE	63.17 ± 12.9	61.47 ± 13.6	0.078
SDH A			
BR	24.21 ± 5.9	20.13 ± 5.3	0.09
BRE	21.89 ± 5.3	19.82 ± 6.2	0.5
SDH B			
BR	12.21 ± 2.3	7.63 ± 2.5	0.0001***
BRE	11.22 ± 2.1	10.24 ± 1.5	0.28
SDH C			

BR	37.03 ± 8.6	28.52 ± 9.9	0.036*
BRE	33.10 ± 6.9	31.50 ± 6.7	0.62
SDH D			
BRE	19.48 ± 3.5	18.97 ± 3.6	0.76
BR	22.08 ± 4.0	18.24 ± 5.6	0.069
PGC-1 α			
BR	0.82 ± 0.23	0.62 ± 0.25	0.031*
BRE	0.78 ± 0.19	0.51 ± 0.10	0.014*
VEGF			
BR	2.90 ± 0.61	2.15 ± 1.13	0.009**
BRE	3.13 ± 1.08	1.66 ± 0.53	< 0.0001***
Myostatin			
BR	0.22 ± 0.09	0.52 ± 0.18	< 0.0001***
BRE	0.22 ± 0.07	0.14 ± 0.04	0.011**

Gene expression levels are expressed as arbitrary units. Values are means \pm SD. SDH A; succinate dehydrogenase a subunit, SDH B; succinate dehydrogenase b subunit, SDH C; succinate dehydrogenase c subunit, SDH D; succinate dehydrogenase d subunit, PGC-1 α ; peroxisome proliferator-activated receptor gamma coactivator-1, VEGF; vascular endothelial growth factor. *, P < 0.05, **, P < 0.01, ***, P < 0.001.

Table 3. Pearson's correlation coefficient (r) of relative changes from PRE to POST in enzyme activity of subjects undergoing 84 d bed rest with (BRE; n = 9) or without (BR; n = 12) flywheel resistance exercise.

	BR	BRE
GS vs. GPh	0.68*	0.55
GS vs. HK	0.77**	0.95**
GS vs. PFK-1	0.56	0.93**
GS vs. CS	0.57*	0.94**
GPh vs. HK	0.65*	0.59
GPh vs. PFK-1	0.54	0.67
GPh vs. CS	0.79**	0.62
HK vs. PFK-1	0.75*	0.99**
HK vs. CS	0.73**	0.99**
PFK-1 vs. CS	0.82**	0.99**

GS; glycogen synthase, GPh; glycogen phosphorylase, HK; hexokinase, PFK-1; phosphofructokinase, CS; citrate synthase. *, P < 0.05, **, P < 0.01.

Table 4. Discriminant analysis by Wilks' Lambda method applied to the non-dimensional ratio ($INC = ([post_value] - [pre_value]) / [pre_value]$). The right column shows the P

value for the difference in INC across groups (i.e. 84 d bed rest vs. 84 d bed rest with resistance exercise).

	Step	1	2	3	4	5	6	P
Myostatin		1.00	0.68	0.67	0.51	0.31	0.22	<0.0001***
GPh (activity)			0.47	0.46	0.34	0.23	0.22	0.006**
GPh (mRNA)				0.35	0.33	0.20	0.16	0.326
SDH B (mRNA)					0.23	0.22	0.18	0.008**
SDH D (mRNA)						0.18	0.15	0.854
HK-2 (mRNA)							0.12	0.046*

GPh; glycogen phosphorylase, SDH B; succinate dehydrogenase b subunit, SDH D; succinate dehydrogenase d subunit, HK-2; hexokinase 2. *, P < 0.05, **, P < 0.01, ***, P < 0.001.